Journal
GLYCOBIOLOGY
Volume 25, Issue 12, Pages 1325-1334Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/glycob/cwv065
Keywords
biologic activity; critical quality attribute; Fc glycans; immunogenicity; therapeutic antibody
Categories
Funding
- Roche Diagnostics GmbH
- Genentech
Ask authors/readers for more resources
Critical quality attributes (CQA) are physical, chemical, biological or microbiological properties or characteristics that must be within an appropriate limit, range or distribution to ensure the desired product quality, safety and efficacy. For monoclonal antibody therapeutics that rely on fraction crystalizable (Fc)-mediated effector function for their clinical activity, the terminal sugars of Fc glycans have been shown to be critical for safety or efficacy. Different glycosylation variants have also been shown to influence the pharmacodynamic and pharmacokinetic behavior while other Fc glycan structural elements may be involved in adverse immune reactions. This review focuses on the role of Fc glycans as CQAs. Fc glycan information from the published literature is summarized and evaluated for impact on patient safety, immunogenicity, bioactivity and pharmacodynamics/pharmacokinetics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available